Samsung Biologics plans sixth facility amid growth, prepares to open Plant 5 in April, expands ADC services, and adds ...

Eli Lilly expects to miss its recent revenue estimate for 2024 by about $400 million, according to a preliminary report.

Four Lykos Therapeutics board members have stepped down and another departed last month, the aftermath of a stalemate over ...

Charles River Laboratories is predicting 2025 to be as tough as last year for CDMOs as pharma customers continue to cut costs ...

Nippon Shinyaku pays $110M upfront to Regenxbio for US/Asia rights to RGX-121 and RGX-111 gene therapies for ...

Private investment firm Bridgewest is combing its Australia-based biologics CDMO BioCina and its sterile injectable ...

The top three pharmacy benefit managers hiked the prices of dozens of 'specialty' generic drugs, some by more than 1000% of ...

Pfizer CEO Bourla outlines company's path forward with new R&D focus, board changes & strategy after meeting Trump, while ...

Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.

IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.

IgA1 reduction in 4 hours, outperforming Vertex's povetacicept and Otsuka's sibeprenlimab. Plans for Phase 3 in IgAN.

XO Health launches health plan in 4 cities, offering employers alternative coverage with fixed-price care packages and ...